Korean biotech reps to arrive next week

While here, they will discuss the possibility of expanding cooperation with Israeli biotech companies, as well as to seek investment opportunities in the country's pharmaceutical companies.

By MATTHEW KRIEGER
May 28, 2007 07:23

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For a symbolic $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Don't show it again

A delegation of representatives from 20 Korean companies in the pharmaceuticals, biotechnology and medical equipment sectors will be arrive here next week for the ISLI-Biomed conference in Tel Aviv. While here, they will discuss the possibility of expanding cooperation with Israeli biotech companies, as well as to seek investment opportunities in the country's pharmaceutical companies. Among the delegation, whose visit is being coordinated the Israel Export Institute, will be some of Korea's largest companies operating in the biotech sector, including LG Life Science, SK, C-Tri and Green Cross.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS